EYPT Up 98% This Month, USNA In Good Health, MDXG To Report Q1 Results
April 25, 2018, 08:21:00 PM EDT By RTT News
Shutterstock photo
(RTTNews.com) - The following are some of today's top gainers in the pharma/biotech sector.
1. EyePoint Pharmaceuticals Inc. (EYPT)
Gained 19.10% to close Wednesday's (Apr.25) trading at $2.37.
News: No news
Recent events:
-- On March 28, 2018, pSivida Corp. (PSDV) acquired specialty biopharmaceutical company Icon Bioscience Inc. -- pSivida Corp. rebranded and changed its name to EyePoint Pharmaceuticals Inc., with ticker EYPT, effective April 2, 2018.
Near-term Catalysts:
-- DEXYCU, a dropless, long-acting therapeutic, which was approved by the FDA for the treatment of inflammation in post cataract surgery on February 9, 2018, is expected to be launched in the U.S. in the first half of 2019 following the successful scale up of commercial supplies. -- The NDA for YUTIQ micro-insert, proposed for treatment of non-infectious posterior segment uveitis, is under FDA review - with a decision expected on November 5, 2018.
- Forums
- ASX - By Stock
- PVA
- Suspension
Suspension
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PVA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online